Contract facts
FederalNo full NAICS 334516 intel page yet. Browse NAICS intelligence
Cancer Reagent Kits - Part Number Change + Decrease Funding is a federal award for 247-Network Contract Office 7 (36C247) held by Roche Diagnostics Corp. Estimated value $541K ($-152,140.48 obligated). Current period of performance ends Sep 28, 2022. Last award drew 3 bidders. Place of performance: INDIANAPOLIS IN.
Cancer reagent kits - part number change + decrease funding. Latest action is a modification.
Recompete timing
PublicCurrent PoP ended Sep 28, 2022 (1485 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Want the durability read on VA24717F1886? One Pursuit Analysis, $500, inside 48 business hours.
- 48 business hours
- $500
- Credits toward the Pack
Incumbent footprint
Public recordRoche Diagnostics Corp — $245.9M obligated across 1,391 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract VA24717F1886?
VA24717F1886 (Cancer reagent kits - part number) is a 247-Network Contract Office 7 (36C247) award with a potential value of $541K, currently held by Roche Diagnostics Corp. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is VA247-17-F-1886?
VA247-17-F-1886 is the dashed form of PIID VA24717F1886 (Cancer reagent kits - part number), held by Roche Diagnostics Corp. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded VA24717F1886?
247-Network Contract Office 7 (36C247) awarded VA24717F1886 to Roche Diagnostics Corp (potential $541K).
Who is the incumbent on VA24717F1886?
Roche Diagnostics Corp is the incumbent with $245.9M across 1391 related awards in SCOUT’s public footprint. The current period of performance ends Sep 28, 2022.
When does Roche Diagnostics Corp’s VA24717F1886 come up for recompete?
SCOUT tracks a period-of-performance end of Sep 28, 2022. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Want the durability read on VA24717F1886? One Pursuit Analysis, $500, inside 48 business hours.
One Pursuit Analysis is $500 and credits toward the Sprint Pack. Delivery is 48 business hours. Start with the free Exposure Check if you want the list first.
No card · under a minute · then the Sprint menu
Use SCOUT in your AI client — $29/moClassify + search inside Claude, ChatGPT, Cursor
Compare plansData: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.